Therapeutic approaches to insulin resistance

Bibliography

• BLOOMGARDEN ZT: Insulin resistance: currentconcepts. Clin. Therap. (1998) 20:216–231.
   PubMed Web of Science ®Google Scholar
• ZIERATH JR, KROOK A, WALLBERG-HENRIKSSON H:Insulin action in skeletal muscle from patients with NIDDM. Mol. Cell. Biochem. (1998) 182:153–160.
   PubMed Web of Science ®Google Scholar
• STEINBERG HO, CHAKER H, LEAMING R, JOHNSON A,BRECHTEL G, BARON AD: Obesity/insulin resistance is associated with endothelial dysfunction. J Clin. Invest. (1996) 97:2601–2610.
   PubMed Web of Science ®Google Scholar
• GRANBERRY MC, FONSECA VA: Insulin resistancesyndrome: options for treatment. South. Med. J (1999) 92:2–14.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Endothelialcell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab. Res. Rev. (1999) 15:274–282.
   PubMed Web of Science ®Google Scholar
• •This review discusses the relationship between oxidant stress, endothelial dysfunction and insulin resistance.
   Google Scholar
• AMOS AF, MCCARTY DJ, ZIMMET P: The rising globalburden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. (1997) 14 (Supp1.5):S1–S85.
   Google Scholar
• PROIETTO J, FILIPPIS A, NAKHLA C, CLARK S: Nutrient-induced insulin resistance. Mol. Cell. Endocrinol. (1999) 1 51:143–149.
   Google Scholar
• TURNER NC, CLAPHAM JC: Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog. Drug Res. (1998) 51:33–94.
   PubMedGoogle Scholar
• SPIEGELMAN BM: PPARy: adipogenic regulator and thiazolidinedione receptor. Diabetes (1998) 48:507–514.
   Google Scholar
• BISHOP-BAILEY D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br. J. Pharmacol (2000) 129:823–834.
   PubMed Web of Science ®Google Scholar
• BARROSO I, GURNELL M, CROWLEY VEF et al: Dominant negative mutations in human PPAR7 associated with severe insulin resistance, diabetes mellitus and hypertension. Nature (1999) 402:880–883.
   PubMed Web of Science ®Google Scholar
• ••This paper highlights the physiological relevance of PPARyin the regulation of insulin sensitivity.
   Google Scholar
• SALTIEL AR, OLEFSKY JM: Perspectives in diabetes: thiazolidinediones in the treatment of insulin resistance and Type II diabetes. Diabetes (1996) 45:1661–1669.
   PubMed Web of Science ®Google Scholar
• BODEN G: Free fatty acids, insulin resistance and Type 2 diabetes mellitus. Proc. Assoc. Am. Physic. (1998) 111:241–248.
   Google Scholar
• MCCARTY MF: Complimentary measures forpromoting insulin sensitivity in skeletal muscle. Med. Hypoth. (1998) 51:451–464.
   Google Scholar
• WIESENBERG I, CHIESI M, MISSBACH M, SPANKA C,PIGNAT W, CARLBERG C: Specific activation of the nuclear receptors PPAR7 and RORA by the antidiabetic thiazolidinedione BRL49653 and the antiarthritic derivative CGP52 608. Mol. Pharmacol. (19 9 8) 53:1131–1138.
   Google Scholar
• HOTAMISLIGIL GS: The role of TNFoc and TNFreceptorsin obesity and insulin resistance. J Ini Med. (1999) 245:621–625.
   PubMed Web of Science ®Google Scholar
• REMESAR X, RAJECAS I, FERNANDEZ LOPEZ JA, ALEMANYM: Is leptin an insulin counter-regulatory hormone? Febs Lett. (1997) 402:9–11.
   Google Scholar
• HENKE BR, BLANCHARD SG, BRACKEEN MF et al.: N-(2-Benzoylpheny1)-L-tyrosine PPAR7 agonists. 1 Discovery of a novel series of potent antihypergly-cemic and antilipidemic agents. J Med. Chem. (1998) 41:5020–5036.
   Google Scholar
• BROWN KK, HENKE BR, BLANCHARD SG et al: A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-7reverses diabetic phenotype of the Zucker diabetic fatty rat. Diabetes (1999) 48:1415–1424.
   PubMed Web of Science ®Google Scholar
• LOVISCACH M, REHMAN N, CARTER L et al: Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action. Diabetologia (2000) 43:304–311.
   PubMed Web of Science ®Google Scholar
• BAILEY, CJ: Potential new treatments for Type 2diabetes. TIPS (2000) 21:259–265.
   PubMed Web of Science ®Google Scholar
• TORRA IP, GERVOIS P, STAELS B: Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. (1999) 10:151–159.
   PubMedGoogle Scholar
• ROSE ML, PAULIK MA, LENHARD JM: Therapeutic approaches to Type 2 diabetes melltius. Exp. Opin. Ther. Patents (1999) 9:1223–1236.
   Web of Science ®Google Scholar
• LENHARD JM, LANCASTER ME, PAULIK MA eta].: The RXR agonist LG100268 causes hepatomegaly, improve glycaemic control and decreases cardiovascular risk and cachexia in diabetic mice suffering from pancre-atic I3-cell dysfunction. Diabetologia (1999) 42:545–554.
   Google Scholar
• MUKHERJEE R, STRASSER J, JOWL, HOENER P, PATERNITI JR, HEYMAN RA: Sensitization of diabetic and obese mice for the use of retinoid X receptor agonists. Nature (1997) 386:407–410.
   PubMed Web of Science ®Google Scholar
• MCCARTY MF: High-dose biotin, an inducer of glucoki-nase expression, may synergise with chromium picolinate to enable a definitive nutritional therapy for Type 2 diabetes. Med. Hypoth. (1999) 52:401–406.
   PubMed Web of Science ®Google Scholar
• ••This paper outlines the potential utility of a nutraceuticaltherapeutic approach to insulin resistance.
   Google Scholar
• COHEN N, HALBERSTAM M, SHLIMOVICH P: Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with NIDDM. J. Clin. Invest. 95:2501-2509.
   Google Scholar
• TSIANI E, FANTUS IG. Vanadium compounds. Biologicalactions and potential as pharmacological agents. Trends Endocrinol. Metab. 8:51–58.
   Google Scholar
• ELCHEBLY M, PAYETTE P, MICHALISYN E et al.: Increased insulin sensitivity and obesity resistance in mice lacking the PTP-113 gene. Science (1999) 283:1544–1548.
   PubMed Web of Science ®Google Scholar
• ••This paper demonstrates a physiological role forphosphatase activity in the regulation of insulin sensitivity and identifies a novel therapeutic target.
   Google Scholar
• ARCH JRS, WILSON S: Prospects for 133-adrenoceptor agonists in the treatment of obesity and diabetes. Int. J. Obesity (1996) 20:191–199.
   Google Scholar
• WEYER C, TATARANNI PA, SNITKER S, DANFORTH E, RAVUSSIN E: Increase in insulin action and fat oxidation after treatment with CL 316, 243, a highly selective beta3-adrenoceptor agonist in humans. Diabetes (1998) 47:1555–1561.
   PubMed Web of Science ®Google Scholar
• SILVA JE, RABELO R: Regulation of the uncoupling protein gene expression. Eur. I Endocrinol (1997) 136:251–264.
   PubMed Web of Science ®Google Scholar
• LARKIN S, MULL E, MIAO W et al: Regulation of the third member of the uncoupling protein family, UCP3, by cold and thyroid hormone. Biochem. Biophys. Res. Comm. (1997) 240:222–227.
   PubMed Web of Science ®Google Scholar
• LAIGHT DW, DESAI KM, GOPAUL NK, CARRIER MJ, ANGGARD EE: F2-isoprostane evidence of oxidant stress in the insulin resistant obese Zucker rat: effects of vitamin E Eur. j Pharmacol. (1999) 377:89–92.
   Google Scholar
• ••This paper provides the first evidence of a role for oxidantstress in insulin resistance in the obese Zucker rat, a model of syndrome X.
   Google Scholar
• LAIGHT DW, DESAI KM, GOPAUL NK, CARRIER MJ, ANGGARD EE: Pro-oxidant challenge in vivo provokes the onset of NIDDM in the insulin resistant obese Zucker rat. Br. J. Pharmacol. (1999) 128:269–271.
   PubMed Web of Science ®Google Scholar
• ••This paper provides the first experimental demonstrationthat oxidant stress can aggravate established insulin resistance and even lead to diabetes.
   Google Scholar
• TIROSH A, POTASHNIK R, BASHAN N, RUDICH A: Oxidative stress disrupts insulin-induced cellular redistribution of IRS-1 and PI3 kinase in 3T3-L1 adipocytes - a putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation. J Biol. Chem. (1999) 274:10595–10602.
   PubMed Web of Science ®Google Scholar
• BERTELSEN M, ANDERSSON MB, ANGGARD EE etal.: Role of reactive oxygen species on trans-endothelial insulin transport. Br. J. Pharmacol. (1998) 125:P120.
   Google Scholar
• GRYGLEWSKI RJ, PALMER RM, MONCADA S: Superoxide anion is involved in the breakdown of endothelium-derived relaxing factor. Nature (1986) 329:454–458.
   Google Scholar
• BARON AD, STEINBERG HO, CHAKER H et al: Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J. Clin. Invest. (1995) 96:779–786.
   Google Scholar
• LAIGHT DW, CARRIER MJ, ANGGARD EE: Antioxidants, diabetes and endothelial dysfunction. Cardiovasc. Res. (2000) 47:457–464.
   PubMed Web of Science ®Google Scholar
• •This review considers the role of antioxidant status in diabetes and discusses the clinical impact of therapeutic antioxidants.
   Google Scholar
• DONNELLY R, QU X: Mechanisms of insulin resistance and new pharmacological approaches to metabolism and diabetic complications. Clin. Exp. Pharmacol. Physiol. (1998) 25:78–87.
   Google Scholar
• HELLER R, MONSCHER-PAULIG F, GRABNER R et al: L-Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol. Chem. (1999) 274:8254–8260.
   PubMed Web of Science ®Google Scholar
• YAWORSKY K, SOMWAR R, KLIP A: Interrelationship between oxidative stress and insulin resistance. In: Anti-oxidants in Diabetes Management. Packer L, Rosen P, Tritschler HJ, King GL, Azzi A (Eds.), Marcel Dekker, Inc., New York, USA (2000):275–302.
   Google Scholar
• •This article highlights the therapeutic utility of a-lipoic acid in the treatment of insulin resistance.
   Google Scholar
• UUSITUPA M, LOUHERANTA A, LINDSTROM J et al.: The Finnish Diabetes Prevention Study. Br. J. Nutt-. (2000) 83:S137–S142.
   Google Scholar
• •This paper demonstrates the feasibility of diabetes preven-tion through diet and exercise.
   Google Scholar
• FUJIMOTO WY: Background and recruitment data for the US Diabetes Prevention Program. Diabetes Care (2000) 23:B11–B13.
   Web of Science ®Google Scholar
• ••This paper provides details of a major clinical trail that aimsto determine the prophylactic value of insulin-sensitising pharmacotherapy in diabetes prevention.
   Google Scholar
• CITROEN HA, TUNBRIDGE FKE, HOLMAN RR: Possible prevention of Type 2 diabetes with acarbose or metformin over 3 years. Diabetologia (2000) 43:A73 290.
   Google Scholar
• ••This abstract indicates the clinical potential of metformin toalleviate primary insulin resistance and prevent or delay diabetes development in subjects at risk as part of the ongoing EDIT.
   Google Scholar